Cargando…
Safety, Tolerability, and Pharmacokinetics of Benralizumab: A Phase 1, Randomized, Single-Blind Study of Healthy Chinese Participants
PURPOSE: Biological therapies targeting eosinophils have been shown to be effective in treating patients with severe eosinophilic asthma. Benralizumab (Fasenra(®), AstraZeneca) is a humanized monoclonal antibody binding to the alpha subunit of the interleukin-5 receptor, which rapidly depletes eosin...
Autores principales: | Cheung, Tommy Tsang, Mai, Tu H, Chia, Yen Lin, Yap, Desmond Y H, Lee, Chi-Ho, Chen, Cecil Chi-Keung, Huang, Ying, Jin, Yuwen, Johnston, James, Werkström, Viktoria, Yao, Yuhui, Ge, Xiaoyun, Zheng, Wenying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885872/ https://www.ncbi.nlm.nih.gov/pubmed/36726737 http://dx.doi.org/10.2147/DDDT.S392155 |
Ejemplares similares
-
Efficacy and Safety of Benralizumab for Korean Patients With Severe, Uncontrolled Eosinophilic Asthma
por: Park, Hae-Sim, et al.
Publicado: (2019) -
Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma
por: Yan, Li, et al.
Publicado: (2019) -
Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma
por: Wang, B, et al.
Publicado: (2017) -
Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
por: Noorduyn, Stephen G., et al.
Publicado: (2021) -
Successful treatment of eosinophilic cystitis with benralizumab
por: Cooke, W Donald, et al.
Publicado: (2020)